Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

147
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
147
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

699
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
699

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective Validation of the Movement Disorder Society Prodromal Multiple System Atrophy Criteria in Pure Autonomic Failure.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Parakinesia in Chorea: Why attribution of intention is misleading.

Parkinsonism & related disorders·2026
Same author

Shortened olfactory identification testing to differentiate parkinsonian syndromes.

Parkinsonism & related disorders·2026
Same author

Long-Term Use of Tiapride and Tetrabenazine in Huntington's Disease: A 25-Year Retrospective Single-Center Analysis.

Clinical therapeutics·2026
Same author

Multiparametric MRI and imaging transcriptomics reveal molecular and cellular correlates of neurodegeneration in experimental Parkinsonism.

NPJ Parkinson's disease·2026
Same author

Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice.

Movement disorders clinical practice·2026

Related Experiment Video

Updated: Dec 29, 2025

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.5K

Cognition in multiple system atrophy: a single-center cohort study.

Sabine Eschlböck1, Margarete Delazer2, Florian Krismer1

  • 1Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Annals of Clinical and Translational Neurology
|February 8, 2020
PubMed
Summary

Cognitive impairment is common in multiple system atrophy (MSA), primarily affecting executive function and verbal memory. The cerebellar subtype showed worse executive function compared to the parkinsonian type.

More Related Videos

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.0K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.6K

Related Experiment Videos

Last Updated: Dec 29, 2025

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.5K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.0K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.6K

Area of Science:

  • Neuroscience
  • Neurology
  • Cognitive Science

Background:

  • Multiple system atrophy (MSA) frequently involves cognitive impairment, yet its characteristics remain poorly understood.
  • Orthostatic hypotension (OH) is a common comorbidity in MSA, but its impact on cognitive function is unclear.

Purpose of the Study:

  • To evaluate cognitive and behavioral features in patients with MSA.
  • To compare cognitive and behavioral differences between MSA subtypes (cerebellar vs. parkinsonian).
  • To assess the effect of orthostatic hypotension (OH) on cognition in MSA patients.

Main Methods:

  • Retrospective study of 54 patients with possible or probable MSA.
  • Comprehensive neuropsychological testing including CERAD-plus, FAB, DST, CLOX1, and HADS-D.
  • Analysis of cognitive profiles and comparison between MSA subtypes and patients with/without OH.

Main Results:

  • Up to 40% of MSA patients exhibited slight to moderate cognitive impairment, predominantly affecting executive functions and verbal memory.
  • Patients with the cerebellar MSA variant performed significantly worse on executive function tests (FAB) and verbal fluency compared to the parkinsonian type.
  • Depression and anxiety were elevated in 28% and 22% of patients, respectively, with no significant difference in cognitive profiles between patients with and without OH.

Conclusions:

  • Cognitive deficits, particularly in executive functions and verbal memory, are frequent in MSA.
  • Further research is needed to differentiate cognitive profiles in synucleinopathies like MSA, Parkinson's disease dementia, and Lewy body dementia.
  • The influence of cardiovascular autonomic dysfunction, such as OH, on cognitive function in MSA requires further investigation.